What is the prevalence of Frontotemporal Degeneration?

Frontotemporal degeneration (FTD) is estimated to affect approximately 15 to 22 per 100,000 individuals, though these figures are likely underestimates due to frequent misdiagnosis. It is considered a rare to uncommon form of early-onset dementia, typically presenting between the ages of 45 and 65, and impacts men and women with roughly equal frequency.

What is the prevalence and incidence of Frontotemporal Degeneration?

Determining the exact prevalence of Frontotemporal degeneration is challenging because it is frequently misdiagnosed as Alzheimer’s disease or psychiatric conditions. According to the NIH GARD and Orphanet, the prevalence is estimated at 15–22 per 100,000 people in the 45–64 age range. The incidence—the rate of new cases—is estimated at approximately 2.7 to 4.1 per 100,000 person-years. Because Frontotemporal degeneration symptoms often mimic other disorders, global epidemiological data likely underrepresents the true burden of the disease.

Who is most commonly affected by Frontotemporal Degeneration?

Frontotemporal degeneration is primarily an adult-onset condition, with the majority of diagnoses occurring between ages 45 and 65. Unlike late-onset dementias, Frontotemporal degeneration is relatively rare in patients over the age of 80. Research indicates no significant gender bias, as it affects both males and females with similar frequency. While there are no major geographic or ethnic variations in prevalence reported, Frontotemporal degeneration is known to have a strong genetic component in 30–50% of cases, which can cause clustering within specific families.

Why is accurate data for Frontotemporal Degeneration difficult to obtain?

Several factors contribute to the difficulty in gathering precise statistics for Frontotemporal degeneration:

• Misdiagnosis: Early symptoms often include personality changes or language difficulties, leading clinicians to misidentify the condition as depression or bipolar disorder.


• Diagnostic Complexity: Definitive diagnosis often requires specialized neuroimaging or genetic testing, which may not be accessible in all regions.


• Community Insights: Real-world patient experiences are vital; currently, 4 people with Frontotemporal degeneration have joined the DiseaseMaps.org community to share their personal journeys and symptom trajectories.

Next steps

• Consult a neurologist or a behavioral neurologist specializing in neurodegenerative conditions for a comprehensive evaluation.


• Seek genetic counseling if there is a known family history of early-onset dementia.


• Connect with the Frontotemporal degeneration community on DiseaseMaps.org to share experiences and track symptom progression.


• Review clinical trial opportunities through the Association for Frontotemporal Degeneration (AFTD).

Medical disclaimer: This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Frontotemporal dementia.


• Orphanet: Frontotemporal dementia.


• The Association for Frontotemporal Degeneration (AFTD): Understanding FTD.


• OMIM (Online Mendelian Inheritance in Man): Frontotemporal dementia.